From the Journals

ICYMI: Andexanet alfa reduces anti–factor Xa activity from apixaban, rivaroxaban


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Patients with acute major bleeding associated with factor Xa inhibitor usage who received andexanet alfa experienced a significant decrease in anti–factor Xa activity, with more than three-quarters of patients experiencing good or excellent hemostatic efficiency after 12 hours. That finding emerged from the multicenter, prospective, open-label, single-group ANNEXA-4 trial published in the New England Journal of Medicine (2019 Feb 11. doi: 10.1056/NEJMoa1814051).

We reported this story at the annual meeting of the American College of Cardiology before it was published in the journal. Find our coverage at the link below.

Recommended Reading

COPD linked to higher in-hospital death rates in patients with PAD
MDedge Cardiology
New recall for CoaguChek test strips issued
MDedge Cardiology
Immunotherapy’s cardiac effects require early monitoring, management
MDedge Cardiology
Biomarkers predict VTE risk with menopausal oral hormone therapy
MDedge Cardiology
Venous thromboembolism risk elevated in ankylosing spondylitis patients
MDedge Cardiology